Dr. Balwani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1184 Fifth Avenue
2ND floor
New York, NY 10029Phone+1 212-241-0915Fax+1 212-426-9065
Education & Training
- Icahn School of Medicine at Mount SinaiResidency, Medical Genetics and Genomics, 2003 - 2006
- Zucker School of Medicine at Hofstra/Northwell at Forest Hills HospitalResidency, Internal Medicine, 2000 - 2003
- Topiwala National Medical CollegeClass of 1997
Certifications & Licensure
- NY State Medical License 2006 - 2025
- American Board of Medical Genetics and Genomics Clinical Genetics
Clinical Trials
- Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact Start of enrollment: 2012 Jul 01
- Oral Iron for Erythropoietic Protoporphyrias Start of enrollment: 2016 Dec 01
Publications & Presentations
PubMed
- Skin α-Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease.Mary Kate LoPiccolo, Zerui Wang, Gadi Maayan Eshed, Luca Fierro, Chanan Stauffer
Movement Disorders. 2024-11-01 - Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.Eliane Sardh, Manisha Balwani, David C Rees, Karl E Anderson, Gang Jia
Orphanet Journal of Rare Diseases. 2024-10-03 - 1 citationsLong-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.Pramod K Mistry, Manisha Balwani, Joel Charrow, Jeremy Lorber, Claus Niederau
American Journal of Hematology. 2024-08-01
Press Mentions
- New Four-Year, $3.26 Million Grant from the National Institute of Neurological Disorders and Stroke Establishes the Mount Sinai Center for Undiagnosed DiseasesSeptember 17th, 2024
- Dersimelagon Increases Duration of Symptom-Free Sunlight Exposure in Erythropoietic Protoporphyria: NEJMApril 20th, 2023
- Dersimelagon Beneficial for Erythropoietic, X-linked ProtoporphyriaApril 13th, 2023
- Join now to see all
Other Languages
- Hindi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: